// App-Quantinova.ai

21587 : Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Researchers

Presenter

  • Jonas Oldgren

Principal Investigators

  • Philippe-Gabriel Steg

  • Stefan H Hohnloser

  • Gregory Y Lip

  • Stephen G Ellis

  • Takeshi Kimura

  • Matias Nordaby

  • Jurrin M ten Berg

  • Deepak L Bhatt

  • Christopher P Cannon

  • Eva Kleine

Medical Centers

  • Uppsala Clinical Research Center and Department of Medical Sciences, Uppsala University, Uppsala, Sweden

  • Dept of Cardiology, Hôpital Bichat, Paris, France

  • Dept of Medicine, Div of Cardiology, Johann Wolfgang Goethe Univ, Frankfurt, Germany

  • Centre for Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom

  • Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

  • Cardiovascular Medicine, Kyoto Univ, Kyoto, Japan

  • TA Cardiology Medicine, Boehringer Ingelheim GmbH, Ingelheim, Germany

  • Pathology, St. Antoniusziekenhuis, Nieuwegein, Netherlands

  • Heart & Vascular Cntr, Brigham and Women's Hosp, Boston, MA

  • Cardiometabolic Trials, Baim Institute for Clinical Rsch, Boston, MA

Locations

  • Sweden

  • France

  • Germany

  • United Kingdom

  • United States

  • Japan

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Clopidogrel bisulfate

  • Pradax

  • Ticagrelor

  • Methadone hydrochloride

  • Warfarin

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

  • Prospective

Phase

  • III

Study Id's

  • NCT02164864

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved